An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab，Mendeley Supplements.

1. Supplemental Materials including: Supplementary Figure 1: Flow diagram of study; Supplementary Figure 2: Numbers of AD patients achieving EASI 25/50/75 at week 2, 4, 8 and week 12. Supplementary Figure 3: Numbers of AD patients achieving SCORAD 25/50/75 at week 2, 4, 8 and week 12. Supplementary Figure 4: Clinical photographs and the EASI score of two typical patients during the follow-up. Supplemental Table 1: Demographic and clinical characteristics of 16 patients. Supplemental Table 2: Laboratory parameters before and during abrocitinib treatment. 2.Supplemental Methods1. 补充材料包含以下内容： 补充图1：研究流程图； 补充图2：第2、4、8及12周时达到EASI（Eczema Area and Severity Index）25/50/75应答的特应性皮炎（Atopic Dermatitis, AD）患者人数； 补充图3：第2、4、8及12周时达到SCORAD（SCORing Atopic Dermatitis）25/50/75应答的AD患者人数； 补充图4：随访期间2例典型患者的临床照片及EASI评分； 补充表1：16例患者的人口学及临床特征； 补充表2：阿布昔替尼（abrocitinib）治疗前及治疗期间的实验室参数。 2. 补充方法